Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Stock data | 2023 | Change |
---|---|---|
Price | $1.93 | N/A |
Market Cap | $12.55M | N/A |
Shares Outstanding | 6.50M | 9.45% |
Employees | 4.00 | N/A |
Shareholder Equity | 3.05M | -77.19% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.86 | N/A |
P/B Ratio | 4.12 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -4.8853 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $0 | N/A |
Earnings | -$14.88M | N/A |
EPS | -2.25 | N/A |
Earnings Yield | -1.17 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $5.92M | N/A |
Cash on Hand | $5.14M | N/A |
Debt to Equity | 0.9424 | 980.12% |
Current Ratio | $2.03 | -83.57% |